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The life-long antiretroviral treatment of HIV-1 infection requires effective and well tolerated medications complemented by high
rates of adherence in order to achieve viral suppression, immunologic reconstitution and to prevent the development of
resistance. Single-tablet regimens (STRs), combining a full antiretroviral regimen in one tablet taken once daily, have been
designed to achieve high adherence and better long-term outcomes. ‘‘STRike’’ is the first cohort study, describing the use of
various STRs in routine clinical practice in Germany. In this observational cohort study 800 participants will be included in 4
treatment arms, treated with the STRs of TDF/FTC/EFV (a retrospective and prospective arm), TDF/FTC/RPV or TDF/FTC/COBI/
EVG after regulatory approval. Patients are followed for at least two years, and reasons for choice of medications and treatment
satisfaction will be collected, in addition to safety, demographic, effectiveness data. To date 344 patients on TDF/FTC/EFV and
123 patients on TDF/FTC/RPV are being followed. In general, the spectrum of patients in the study reflects the German HIV-1
infected population with regards to gender (88%/89% male), age (median 40/38 years of age) and mode of infection (71%/63%
MSM). However, patients starting TDF/FTC/RPV are less progressed in their disease according to their CDC stage compared with
patients on TDF/FTC/EFV (74.5% stage ‘‘A’’ vs. 53.2%). Patients starting TDF/FTC/RPV show less comorbidities (54% vs. 82%) with
a spectrum different from patients on TDF/FTC/EFV. Pre-existing neuropsychiatric comorbidities are relatively more common
(10% more) among patients starting TDF/FTC/RPV than TDF/FTC/EFV. The decision to use an STR is mostly driven by patient
preference to start with a more convenient ART regimen (56%) or to simplify their current ARTregimen (75%). STRs aim to make
treatment of HIV more convenient, more efficacious and more durable and by that allowing for earlier initiation of treatment.
Different STRs may meet the requirements of distinct patient populations. TDF/FTC/RPV in this early review of our data, is
utilized by younger patients with fewer overall comorbidities, but is selected more frequently for patients with pre-existing
neuropsychiatric comorbidities presumably to avoid the known neuropsychiatric complications of TDF/FTC/EFV. TDF/FTC/RPV
appears to fit into the concept of early HIV treatment initiation as recommended by national and international guidelines.
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